ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstracts tagged "biologic response modifiers and rheumatoid arthritis (RA)"

  • Abstract Number: 458 • 2012 ACR/ARHP Annual Meeting

    Better Retention RATE At 5 YEARS of ANTI-TNF Agents USED in Conjonction with Methotrexate Over Time in Patients with Rheumatoid Arthritis: REAL-Life DATA From Rhumadata Computarized Database

    Denis Choquette1, Diane Sauvageau2, Boulos Haraoui2 and Jean-Pierre Raynauld2, 1Rheumatology, Institut de Rhumatologie De Montréal, Montreal, QC, Canada, 2Rheumatology, Institut de Rhumatologie de Montréal, Montreal, QC, Canada

    Background/Purpose: Anti-TNF agents have been in used in Canada for the last ten years. Although a vast body of clinical experience has been accumulated since…
  • Abstract Number: 1246 • 2012 ACR/ARHP Annual Meeting

    Cardiovascular Risk Assessment in Rheumatoid Arthritis (RA) Patients Treated by Biologic Response Modifiers

    Majed M. Khraishi1, Rana Aslanov2 and Katie Doyle1, 1Nexus Clinical Research, Memorial University of Newfoundland, St Johns, NF, Canada, 2Clinical Epidemiology Department, Faculty of Medicine, Memorial University of Newfoundland, St.John's, NF, Canada

    Background/Purpose: We aimed to assess the 10-year CV event risk in patients with RA at the baseline and 1 year after the initiation of treatment…
  • Abstract Number: 1332 • 2012 ACR/ARHP Annual Meeting

    The Incidence of Exacerbation of Pre-Existing Interstitial Lung Disease (ILD) Is Higher in TNF Blockers Than in Non-TNF Blockers in RA

    Tamao Nakashita1, Shinji Motojima2, Natsuki Fujio2 and Akira Jibatake3, 1Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa City, Japan, 2Department of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan, 3Depertment of Rheumatology and Allergy, Kameda Medical Center, Kamogawa city, Japan

    Background/Purpose: Exacerbation of interstitial lung disease (ILD) is a problem when biologics are administrated in patients with RA, and not a few fatal cases have…
  • Abstract Number: 1841 • 2012 ACR/ARHP Annual Meeting

    Lower Than Expected Levels of DMARD Acquisition Immediately Pre and Post Biologic Initiation in Rheumatoid Arthritis Patients

    Denis Choquette1, Oliver Thomas2 and Mark Arundine2, 1Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 2Roche, Toronto, ON, Canada

    Background/Purpose: Reports suggest that a large proportion of patients who acquire and use biologic DMARD agents (biologics) to treat Rheumatoid Arthritis (RA) do not acquire…
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
This site uses cookies: Find out more.